Gilead Sciences Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Roger Ebert1d
In “The Handmaid’s Tale,” Women Fight the Darkness—And Are Tempted By It
Hulu's dystopian series continues to demonstrate the ways patriarchy chips away at the women subjugated by it.
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $140.00 at Wells Fargo & Company
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...
2025 OHSAA state wrestling: Live results from Division III
OHSAA wrestling championships get underway Friday at the Schottenstein Center in Columbus. Follow the Division III results ...
Zacks Investment Research on MSN16hOpinion
Buy Gilead Sciences (GILD) Stock at 52-Week Highs?
Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply ...
The Japan Times2d
Gilead's Japan head says nation can be among first to end HIV epidemic
The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...
Gilead price target raised to $126 from $116 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...
Oppenheimer Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...
Fierce Pharma4d
Gilead sets aside $200M for potential settlement over HIV drug speaker program
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
Gilead price target raised to $132 from $115 at Oppenheimer
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...
7GILD : P/E Ratio Insights for Gilead Sciences
Gilead Sciences has a better P/E ratio of 305.37 than the aggregate P/E ratio of 65.67 of the Biotechnology industry. Ideally, one might believe that Gilead Sciences Inc. might perform better in the ...